Phase 3 outcomes (2026): TRIUMPH-1 (May 2026, n=2,339) demonstrated 28.3% mean weight loss at 12mg weekly the largest published Phase 3 result of any GLP-1 class compound to date, exceeding tirzepatide (22.5% in SURMOUNT-1) and semaglutide (14.9% in STEP-1) at comparable timepoints
The down-regulation of lactoferrin expression induced by cigarette smoke can induce ferroptosis in COPD
Renowned for its regenerative properties, BPC-157 has been studied for its ability to support healing across various tissues, such as muscles, tendons, ligaments, and even the gastrointestinal (GI) tract
Packed with electrolytes, this IV will have you feeling good as new
In summary, both natural polypeptides and recombinant polypeptides exhibit great potential in antitumor applications